PMC:7556165 / 67205-67389
Annnotations
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T371 | 92-102 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
| T372 | 92-96 | Species | denotes | SARS | NCBItxid:694009 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T398 | 0-184 | Sentence | denotes | Following this data, ADAM17 inhibition was proposed as a possible pharmacological target in SARS-CoV-2, but further studies are needed to evaluate this hypothesis (Palau et al., 2020). |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 1834 | 21-27 | Gene | denotes | ADAM17 | Gene:6868 |
| 1835 | 92-102 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T6109 | 21-27 | Protein | denotes | ADAM17 | https://www.uniprot.org/uniprot/Q9Z1K9|https://www.uniprot.org/uniprot/Q9Z0K3|https://www.uniprot.org/uniprot/Q9Z0F8|https://www.uniprot.org/uniprot/Q9R1U4|https://www.uniprot.org/uniprot/Q505A7|https://www.uniprot.org/uniprot/P78536|https://www.uniprot.org/uniprot/O88726|https://www.uniprot.org/uniprot/O77636|https://www.uniprot.org/uniprot/O60226 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T386 | 92-102 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T387 | 92-96 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1834 | 21-27 | Gene | denotes | ADAM17 | Gene:6868 |
| 1835 | 92-102 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T398 | 0-184 | Sentence | denotes | Following this data, ADAM17 inhibition was proposed as a possible pharmacological target in SARS-CoV-2, but further studies are needed to evaluate this hypothesis (Palau et al., 2020). |